The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE’s Single Technology Appraisal process, is to review the submission received from Shire Pharmaceuticals on the clinical and cost-effectiveness of Atezolizumab monotherapy (Tecentriq®) for untreated advanced non-small-cell lung cancer. The main source of evidence submitted by Shire Pharmaceuticals, consists of a Phase III, multicentre, open-label RCT (IMpower110). The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from Shire Pharmaceuticals and the ERG’s critique, NICE will release appropriate clinical guidance.
For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10587
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk